top of page
  • Writer's pictureinsightclinicaltri

Paving the Way Towards Better Treatment for Schizophrenia

Updated: Sep 24, 2020

Managing medications and symptoms of schizophrenia can be very difficult. Insight Clinical Trials is now enrolling participants in research studies that may help people reduce symptoms and make taking medication easier.

There are more than 21 million people around the world living with schizophrenia, a mental health disorder that can have a serious impact on physical health, relationships, ability to work, and overall quality of life. For many, the medications currently available to manage schizophrenia do not fully control their symptoms.

In the ALIGHT schizophrenia study, researchers want to find out if the study drug is safe and effective in helping to treat schizophrenia in adults who continue to have serious symptoms even while taking antipsychotic medication(s).

The ALIGHT schizophrenia clinical research study is a phase 2b study to investigate the safety and efficacy of GWP42003-P as adjunctive therapy in participants with schizophrenia experiencing inadequate response to ongoing antipsychotic treatment.

GWP42003-P is a formulated oral solution of cannabidiol (CBD). This randomized, double-blind, parallel-group study will compare treatment with GWP42003-P at two dose levels to placebo.

To pre-qualify for this ALIGHT schizophrenia clinical research study, a person must meet all of the following criteria:

  • 18 to 50 years of age

  • Diagnosed with schizophrenia

  • Clinically stable outpatient

  • Score of ≥ 4 for at least 2 of the following PANSS items: delusions, conceptual disorganization, hallucinatory behavior, suspiciousness, or unusual thought content

  • Undergoing treatment with at least 1, and a maximum of 2, antipsychotic medications

Please note that this is not the full list of study eligibility criteria. Study enrollment is currently active, and visits are conducted at Insight Clinical Trials in Beachwood, Ohio.

There will be no charge to study participants for their participation in this clinical research study. The study drug, study-related procedures, and study visits will be provided at no charge.

Call 216-526-1843 to learn more or schedule a free consultation

or share your email address through this form.

24 views0 comments


bottom of page